ARTICLE | Clinical News
BVF-033 regulatory update
December 3, 2007 8:00 AM UTC
FDA accepted a complete response from BVF to a July not approvable letter for BVF-033 to treat depression. The company said the response was classified as a Class 2 resubmission, which results in a PD...